Clinical Trials Browser

Phase 2/3 × OTHER × G250 monoclonal antibody × Clear all

NCT02883153 2017-06-19

Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma

Phase 2/3 Completed

Carcinoma, Renal Cell